Cuts FY23 revenue view to $625M-$645M from $640M-$660M, consensus $654.5M.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MDRX:
- Veradigm, HealthVerity team on research and care for patients with CVD
- Veradigm downgraded to Neutral from Overweight at Piper Sandler
- Piper Sandler healthcare tech analysts to hold analyst/industry conference call
- Veradigm sees FY23 EPS 90c-$1.00, consensus 95c
- Veradigm announces new $250M share repurchase program